摘要
目的探讨臭氧自血疗法(O3-AHT)辅助治疗慢性心力衰竭(CHF)患者的疗效及安全性。方法收集2018年7月至2019年6月在浙江大学医学院附属金华医院住院的CHF患者60例,采用随机数字表法分为O3-AHT组和对照组,每组30例。比较两组治疗前后脑钠肽(BNP)水平、6 min步行试验(6MWT)距离及治疗前、治疗后6个月心功能指标,观察O3-AHT不良反应,随访两组患者6个月期间心血管事件的发生情况。结果两组治疗后BNP均较治疗前显著下降、6MWT距离增加(均P<0.05),O3-AHT组更为明显(均P<0.05)。两组治疗后6个月左心室舒张末期内径(LVEDd),左心室收缩末期内径(LVESd)均降低,左心室射血分数(LVEF)升高(均P<0.05),O3-AHT组改善更加显著(均P<0.05)。O3-AHT组出现穿刺处出血1例,两组不良反应发生率比较差异无统计学意义(P>0.05)。O3-AHT组6个月内心血管不良事件发生率低于对照组,但差异无统计学意义(P>0.05)。结论O3-AHT辅助治疗CHF患者安全有效。
Objective To investigate the clinical efficacy and safety of adjuvant ozone autohemotherapy(O3-AHT)in the treatment of chronic heart failure(CHF).Methods 60 inpatients in Jinhua Municipal Central Hospital from July 2018 to June 2019 with CHF were randomly divided into O3-AHT group and control group.The levels of B-type natriuretic peptide(BNP),6-minute walking test(6MWT)and echocardiographic parameters were measured before and after the treatment and compared between the two groups.The adverse reactions of O3-AHT and cardiovascular events during follow-up 6 months were observed.Results After treatment,BNP decreased and 6MWT improved significantly in both groups(all P<0.05),especially in O3-AHT group(all P<0.05).Left ventricular end diastolic diameter(LVEDd)and LV end systolic diameter decreased(LVESd)significantly and LV ejection fraction(LVEF)increased significantly after 6 months of treatment in both groups(all P<0.05),especially in the O3-AHT group(all P<0.05).One case of hemorrhage in the puncture site occurred in the O3-AHT group.The incidence of cardiovascular adverse events in the O3-AHT group within 6 months was insignificantly lower than that in the control group,but no significantly difference was found between the two groups(P>0.05).Conclusion Adjuvant O3-AHT is safety and effective in the treatment of CHF.
作者
杨伊萍
傅慎文
钟鸣
何建荣
何鸣皓
YANG Yiping;FU Shenwen;ZHONG Ming;HE Jianrong;HE Minghao(Department of Cardiology,Affiliated Jinhua Hospital,Zhejiang University School of Medicine,Jinhua 321000,China)
出处
《心电与循环》
2020年第4期360-363,共4页
Journal of Electrocardiology and Circulation
基金
金华市科技计划项目(2018-4-012)。
